Mental Health Survey Reveals Available Antidepressants Aggravate Sexual Dysfunction and Make Depression Worse
Research Reports on Drug Makers Equities — Bristol-Myers Squibb, AstraZeneca, TherapeuticsMD, and Impax Laboratories
Drug manufacturing companies develop and process pharmaceutical products for a wide range of medical uses and offer slightly higher-than-average dividend yields. Driving demand for pharmaceuticals is the need to remedy illnesses and diseases. Stock-Callers.com highlights four major industry players for review: Bristol-Myers Squibb Co., AstraZeneca PLC, TherapeuticsMD Inc., and Impax Laboratories Inc. Bristol-Myers Squibb New York headquartered…
OWC Pharmaceutical Research Corp to Initiate Efficacy Testing on its Cannabinoid-Infused Cream for Treatment of Psoriasis
China Biologic Receives CFDA Clinical Trial Approval for Human Antithrombin III
Allergan to Obtain Rights to Inflammatory Disorder Program from AstraZeneca
Allergan plc enters into licensing agreement with AstraZeneca to obtain worldwide rights to MEDI2070 inflammatory disorder development program. Allergan plc has entered into a licensing agreement with MedImmune, AstraZeneca’s global biologics research and development arm, for the global rights to MEDI2070. MEDI2070 is an anti-IL-23 monoclonal antibody currently in Phase IIb clinical development for the…
TapImmune Recognizes National Breast Cancer Awareness Month With Renewed Urgency to Develop Cancer Vaccines
TapImmune, Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is celebrating the month of October by reinforcing its efforts to prevent and cure breast and ovarian cancer. In an open letter posted on the TapImmune website, the company’s…
600+ Astellas Employees Across the U.S. & Brazil Participate in the Company’s 7th Annual Global Day of Service
More than 600 Astellas employees to give back to local communities across the U.S. and Brazil for Changing Tomorrow Day – the company’s 7th annual global day of service. Today, more than 600 Astellas employees on two continents will get out of their offices, roll up their sleeves, and help their communities. This will be…
Biotechs and the Advancements in Cancer Oriented Clinical Trials
AcelRx Initiates Phase 3 Study of Post-Operative Pain Treatment
Study: OncBioMune Cancer Vaccine in Early & Advanced Prostate Cancer
Athenex & SunGen Join Forces for a Portfolio of 7 Approved Pharma Products
FDA Approves Janssen’s Crohn’s Disease Treatment
Allergan Acquires Akarna Therapeutics, Adding to NASH Pipeline
Allergan acquires Akarna Therapeutics adding to its strong development program and commitment to innovation in NASH. Allergan plc, a leading global pharmaceutical company, announced that the Company has acquired Akarna Therapeutics Ltd., a privately held biopharmaceutical company focused on developing novel small molecule therapeutics that target inflammatory and fibrotic diseases, for an up-front payment of $50…
Stock Review: Pfizer, Merck, AbbVie, and Johnson & Johnson
GSK’s Shingles Vaccine Shows High Efficacy in Phase 3 Study
Kalorama: As Mylan Attracts Controversy, Overall Trend in Pharma is Falling Revenues and Prices
Generic Drugs Stocks Technical Reports — Mylan, Horizon Pharma, Allergan, and Akorn
Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper generic drugs. Stock-Callers.com presents four stocks within the generic drugs space for review, one of which has dominated the headlines just recently. Let’s take a look at our featured companies: Mylan N.V., Horizon Pharma PLC, Allergan PLC,…
Perrigo Receives Tentative FDA Approval of Generic Drug & Has Patent Challenged
Perrigo Company plc has received tentative approval from the U.S. FDA for the generic version of Suprep® (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution. The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults. Annual sales for the past 12 months ending July 2016 were $178 million. Perrigo also announced that it was…
Bayer & CRISPR’s Joint Venture to Cure Blood Disorders, Blindness, & Congenital Heart Disease
Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therapeutics agreed to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. The two parties formally closed the transaction…
Astellas Farma Brasil Ranked Among 20 Greatest Workplaces in Brazil
For the second consecutive year, the pharmaceutical company was named to the 2016 Great Place to Work® ranking among medium-sized multinational businesses in the country. Astellas Farma Brasil (AFB) is among the 20 best medium-sized (100-999 employees) multinational companies to work for across all industries in the country, according to the Great Place to Work®…
Cannabis Makes Headway in Mainstream Pharma: Development of Cancer Treatments & More Using Cannabis Strains
The medical sector of the cannabis industry continues to explode behind constant research and innovative studies for identifying viable cancer treatments and other therapies for different ailments. Increased research through pioneering trials and studies including for example, evaluations in rodents allowing a few select companies to reach breakthroughs. Veritas Pharma Veritas Pharma Inc., an emerging…
Key Players, Disease Indications, & More in the Vaccine Market: 2021 Predictions
Medical Aesthetics Market Worth $69,786 Million by 2021
The current medical aesthetic market is worth $52,405 million for both service and product revenue, which over the next five years will grow at 5.5 percent CAGR and is expected to hit $69,786 million in 2021, according to an analysis. The invasive aesthetic procedures are set to grow at a CAGR of 4.3%, while non-invasive…